LMR Partners LLP Grows Holdings in Glaukos Co. (NYSE:GKOS)

LMR Partners LLP boosted its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 12.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 36,986 shares of the medical instruments supplier's stock after buying an additional 4,059 shares during the period. LMR Partners LLP owned 0.07% of Glaukos worth $4,819,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. purchased a new stake in shares of Glaukos in the second quarter valued at about $6,832,000. Natixis acquired a new stake in shares of Glaukos during the 1st quarter worth approximately $614,000. Vanguard Group Inc. raised its position in shares of Glaukos by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier's stock valued at $500,576,000 after buying an additional 72,159 shares during the period. UniSuper Management Pty Ltd acquired a new position in Glaukos in the first quarter valued at approximately $913,000. Finally, WCM Investment Management LLC increased its stake in Glaukos by 45.7% during the third quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier's stock worth $12,721,000 after acquiring an additional 31,084 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of research analyst reports. StockNews.com upgraded Glaukos from a "sell" rating to a "hold" rating in a report on Monday, October 21st. JPMorgan Chase & Co. lifted their price target on shares of Glaukos from $130.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Wells Fargo & Company upped their price objective on shares of Glaukos from $135.00 to $145.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Truist Financial lifted their target price on shares of Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a report on Monday, October 14th. Finally, Needham & Company LLC upped their price target on Glaukos from $131.00 to $137.00 and gave the stock a "buy" rating in a research note on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $134.55.

Glaukos Stock Performance

Shares of Glaukos stock traded up $7.12 on Tuesday, reaching $144.10. 419,951 shares of the company were exchanged, compared to its average volume of 574,872. The stock's 50 day moving average price is $130.92 and its 200-day moving average price is $122.57. Glaukos Co. has a 1-year low of $59.22 and a 1-year high of $145.84. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company's quarterly revenue was up 23.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.50) EPS. Research analysts anticipate that Glaukos Co. will post -1.96 EPS for the current year.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 3,000 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at approximately $4,225,345.12. This represents a 8.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at $14,198,425.93. This represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,275 shares of company stock valued at $1,354,967 in the last ninety days. Insiders own 6.40% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.